AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34919488 — intervention group
Group type: COMPARATOR
Intervention: hobby-designed website
Number of subjects: 10
Study 32174355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballpoint pens with specific physical properties (comfortable, fine, refined, deep, natural, heavier, longer, thick and antislip grips, thin nibs, center of gravity close to nib)
Number of subjects: 0
Study 35644376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic Intervention (CI)
Number of subjects: 400
Study 35644376 — intervention group
Group type: EXPERIMENTAL
Intervention: CI with Home Visits (HV)
Number of subjects: 400
Study 35644376 — intervention group
Group type: EXPERIMENTAL
Intervention: CI and real-time feedback to asthma clinician
Number of subjects: 400
Study 35644376 — intervention group
Group type: EXPERIMENTAL
Intervention: CI with HVs and real-time feedback
Number of subjects: 400
Study 33565123 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community case management (iCCM)
Number of subjects: 5898
Study 33218540 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib Raising (RR) technique
Number of subjects: 32
Study 33218540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth Ventricle Compression Technique (CV4)
Number of subjects: 32
Study 33218540 — intervention group
Group type: COMPARATOR
Intervention: CV4
Number of subjects: 32
Study 35060507 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic device (LSM-01)
Number of subjects: 0
Study 35060507 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control group)
Number of subjects: 0
Study 34344546 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 21
Study 34344546 — intervention group
Group type: COMPARATOR
Intervention: isocaloric placebo
Number of subjects: 21
Study 35275197 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 159
Study 35275197 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 159
Study 33710319 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker prescription
Number of subjects: 111718
Study 33710319 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol
Number of subjects: 111718
Study 32139762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (>90% VO2max)
Number of subjects: 12
Study 32139762 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60-75% VO2max)
Number of subjects: 12
Study 32139762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (<60% VO2max)
Number of subjects: 12
Study 32139762 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise sessions
Number of subjects: 12
Study 36532821 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril breathing (RNB)
Number of subjects: 164
Study 36532821 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril breathing (LNB)
Number of subjects: 164
Study 36532821 — intervention group
Group type: COMPARATOR
Intervention: Alternate nostril breathing (ANB)
Number of subjects: 164
Study 36532821 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing (NB)
Number of subjects: 164
Study 34701377 — intervention group
Group type: EXPERIMENTAL
Intervention: DI IMPT(chemo)
Number of subjects: 71
Study 34701377 — intervention group
Group type: COMPARATOR
Intervention: IMRT(chemo)
Number of subjects: 71
Study 32978194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation nursing by trained and qualified nurses (7 days, 2 sessions per day, 30 min each session)
Number of subjects: 224
Study 32978194 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation provided by therapists (7 days, 2 sessions per day, 30 min each session)
Number of subjects: 224
Study 32978194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation nursing by trained and qualified nurses
Number of subjects: 224
Study 32978194 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation provided by therapists
Number of subjects: 224
Study 35887551 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (ILO) inhalation
Number of subjects: 64
Study 35887551 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 64
Study 32118565 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound devices (HUDs)
Number of subjects: 149
Study 32118565 — intervention group
Group type: COMPARATOR
Intervention: No handheld ultrasound devices (no-HUDs)
Number of subjects: 149
Study 32118565 — intervention group
Group type: EXPERIMENTAL
Intervention: 2017 cohort (HUDs and no-HUDs combined)
Number of subjects: 149
Study 32118565 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated lecture series
Number of subjects: 149
Study 32533427 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin loading procedure
Number of subjects: 60
Study 32533427 — intervention group
Group type: COMPARATOR
Intervention: Glucose loading procedure
Number of subjects: 60
Study 33797658 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative analgesia (PRE group) using celecoxib, meloxicam or rofecoxib from 2 hours pre-operation to 48 hours post-operation
Number of subjects: 464
Study 33797658 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesia (POST group) using celecoxib, meloxicam or rofecoxib from 4 to 48 hours post-operation
Number of subjects: 464
Study 33797658 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative analgesia (PRE group)
Number of subjects: 464
Study 33797658 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of analgesics (meloxicam, celecoxib, rofecoxib)
Number of subjects: 464
Study 34455503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted group implants (2 anterior axial and 2 posterior distally inclined implants)
Number of subjects: 20
Study 34455503 — intervention group
Group type: COMPARATOR
Intervention: Axial group implants (2 implants in the interforaminal area and 2 in the molar area)
Number of subjects: 20
Study 33326656 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal combined with preventive medication (W+P)
Number of subjects: 120
Study 33326656 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal with optional preventive medication (W)
Number of subjects: 120
Study 33326656 — intervention group
Group type: COMPARATOR
Intervention: Preventive medication without withdrawal (P)
Number of subjects: 120
Study 35261290 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management strategy
Number of subjects: 777
Study 35261290 — intervention group
Group type: COMPARATOR
Intervention: Conservative management strategy
Number of subjects: 777
Study 33529350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens and cosmetic formulations containing ascorbyl tetraisopalmitate and rice peptides
Number of subjects: 60
Study 33991686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered mobile health technology intervention (iCardia4HF) including Heart Failure Storylines app, connected health devices (Withings weight scale, blood pressure monitor, Fitbit activity tracker), and tailored text messages
Number of subjects: 92
Study 33991686 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving connected health devices without the HF self-care app and text messages
Number of subjects: 92
Study 33991686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered mobile health technology intervention (iCardia4HF)
Number of subjects: 92
Study 33991686 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 92
Study 35428613 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 400/57 suspension
Number of subjects: 271
Study 35428613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 33121997 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month CAPOX
Number of subjects: 514
Study 33121997 — intervention group
Group type: COMPARATOR
Intervention: 6-month CAPOX
Number of subjects: 514
Study 33121997 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month mFOLFOX6
Number of subjects: 514
Study 33121997 — intervention group
Group type: COMPARATOR
Intervention: 6-month mFOLFOX6
Number of subjects: 514
Study 32252680 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent EP (etoposide + cisplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Number of subjects: 71
Study 32252680 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent PC (paclitaxel + carboplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Number of subjects: 71
Study 33988909 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention for elderly Alzheimer Disease patients
Number of subjects: 150
Study 33988909 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention for caregivers of elderly Alzheimer Disease patients
Number of subjects: 150
Study 33988909 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (Control group)
Number of subjects: 150
Study 34237489 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model and elastic net regression model
Number of subjects: 1055
Study 34237489 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic net algorithm
Number of subjects: 1055
Study 34237489 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score calculation
Number of subjects: 1055
Study 34237489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrapping internal verification method (R = 1000)
Number of subjects: 1055
Study 35945745 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with intravenous ibuprofen (10 mg/kg) administered once within 6 hours after birth
Number of subjects: 69
Study 35945745 — intervention group
Group type: COMPARATOR
Intervention: Non-prophylactic treatment (non-PT)
Number of subjects: 69
Study 35945745 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with intravenous ibuprofen (10 mg/kg)
Number of subjects: 69
Study 34911530 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided approach to periodontal infection control (GPIC)
Number of subjects: 494
Study 34911530 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-surgical therapy (CNST)
Number of subjects: 494
Study 34911530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GPIC and CNST
Number of subjects: 494
Study 35441313 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 24
Study 35441313 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 24
Study 33604941 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen (UFT 300 mg/m2 per day, LV 50 mg per day)
Number of subjects: 386
Study 33604941 — intervention group
Group type: COMPARATOR
Intervention: Three-times-daily regimen (UFT 300 mg/m2 per day, LV 75 mg per day)
Number of subjects: 386
Study 35879001 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained palliative care educators and video decision aids
Number of subjects: 9000
Study 33453756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with radiotherapy
Number of subjects: 0
Study 33453756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab without radiotherapy
Number of subjects: 0
Study 32739049 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1795091 (30 participants)
Number of subjects: 40
Study 32739049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 participants)
Number of subjects: 40
Study 35927627 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) + best medical treatment (BMT)
Number of subjects: 200
Study 35927627 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 200
Study 32990234 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (n=120)
Number of subjects: 180
Study 32990234 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (n=60)
Number of subjects: 180
Study 35013089 — intervention group
Group type: EXPERIMENTAL
Intervention: TI-CBT Enhanced (TI-CBTe)
Number of subjects: 356
Study 35013089 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (time-matched, unstructured support groups)
Number of subjects: 356
Study 34324933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 μg.kg-1) followed by propofol (1 mg.kg-1) after 1 minute
Number of subjects: 186
Study 34324933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 μg.kg-1) followed by propofol (2 mg.kg-1) after 2 minutes
Number of subjects: 186
Study 34324933 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1 min and 2 min with varying doses of propofol)
Number of subjects: 186
Study 34324933 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study 32167611 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-energy enteral feeding starting at 75% of daily energy expenditure, increasing to 90%-100%.
Number of subjects: 58
Study 32167611 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric enteral feeding starting with 30% of daily energy expenditure, reaching 75% within 7 days.
Number of subjects: 58
Study 32167611 — intervention group
Group type: COMPARATOR
Intervention: Full-energy enteral feeding (control group).
Number of subjects: 58
Study 35176136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 554
Study 35176136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 554
Study 35176136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Bevacizumab and Cetuximab plus chemotherapy
Number of subjects: 554
Study 34493225 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving Babies? Lives programme (intervention)
Number of subjects: 6615
Study 34493225 — intervention group
Group type: COMPARATOR
Intervention: Standard government service (control)
Number of subjects: 6615
Study 34706141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib in the deferred arm (n=48)
Number of subjects: 88
Study 34706141 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib in the immediate arm (n=40)
Number of subjects: 88
Study 34706141 — intervention group
Group type: COMPARATOR
Intervention: Immediate CN
Number of subjects: 88
Study 34706141 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred CN
Number of subjects: 88
Study 34706141 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib treatment duration in immediate arm
Number of subjects: 88
Study 34706141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib treatment duration in deferred arm
Number of subjects: 88
Study 34545166 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular AVG training (AVG-R)
Number of subjects: 64
Study 34545166 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced AVG training (AVG+)
Number of subjects: 64
Study 34545166 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual comparison group
Number of subjects: 64
Study 36420043 — intervention group
Group type: EXPERIMENTAL
Intervention: infant‐mCIMT
Number of subjects: 0
Study 36420043 — intervention group
Group type: EXPERIMENTAL
Intervention: infant‐BIT
Number of subjects: 0
Study 36420043 — intervention group
Group type: EXPERIMENTAL
Intervention: infant‐hybrid
Number of subjects: 0
Study 36420043 — intervention group
Group type: COMPARATOR
Intervention: infant standard therapy
Number of subjects: 0
Study 32193820 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + DL
Number of subjects: 60
Study 32193820 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 36058824 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage with ginger and lavender oil for 15 min, 5 weekdays per week for 4 weeks
Number of subjects: 40
Study 36058824 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 40
Study 36482652 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intubation
Number of subjects: 76
Study 36482652 — intervention group
Group type: COMPARATOR
Intervention: Routine intubation
Number of subjects: 76
Study 33693616 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Self-Reporting Questionnaire (SRQ)
Number of subjects: 0
Study 33693616 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Kessler-6 screening questionnaire
Number of subjects: 0
Study 33693616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both questionnaires
Number of subjects: 0
Study 35448895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal incobotulinumtoxinA (Xeomin®) 100 U as an add-on therapy
Number of subjects: 66
Study 34217604 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on mammographic positioning
Number of subjects: 24
Study 32777664 — intervention group
Group type: EXPERIMENTAL
Intervention: App group (UroHealth app)
Number of subjects: 100
Study 32777664 — intervention group
Group type: COMPARATOR
Intervention: Control group (validated printed questionnaires)
Number of subjects: 100
Study 35989239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor exercises for five weeks
Number of subjects: 70
Study 33529664 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg dose)
Number of subjects: 2058
Study 33529664 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban concentration
Number of subjects: 2058
Study 33529664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Factor Xa activity
Number of subjects: 2058
Study 33529664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogenic anti-Factor Xa activity assay
Number of subjects: 2058
Study 33529664 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2058
Study 34986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle (CON) technique
Number of subjects: 60
Study 34986793 — intervention group
Group type: COMPARATOR
Intervention: Catheter-through-needle (CTN) technique
Number of subjects: 60
Study 34986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received CFNB and sciatic nerve block with 0.16% levobupivacaine and 6 mg indigo carmine at 6 ml/h
Number of subjects: 60
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 month
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 18 months
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with fatigue
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with depressive symptoms
Number of subjects: 734
Study 33136703 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with quality of life
Number of subjects: 734
Study 32970172 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐lactam antibiotic treatment for less than seven days
Number of subjects: 16
Study 32970172 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 16
Study 35583488 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids (AAS)
Number of subjects: 0
Study 35583488 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33627069 — intervention group
Group type: EXPERIMENTAL
Intervention: FindMyApps intervention (tablet computer and FindMyApps)
Number of subjects: 150
Study 33627069 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm - tablet computer)
Number of subjects: 150
Study 32757479 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin plus ice stimulation
Number of subjects: 0
Study 32757479 — intervention group
Group type: COMPARATOR
Intervention: Ice stimulation (control)
Number of subjects: 0
Study 35215431 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% taro flour + 50% wheat flour
Number of subjects: 15
Study 35215431 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% taro flour + 50% wheat flour + probiotic L. plantarum IS‐10506
Number of subjects: 15
Study 35215431 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% taro flour + 50% wheat flour + beetroot adsorbed
Number of subjects: 15
Study 34078342 — intervention group
Group type: COMPARATOR
Intervention: Physical activity intervention (iPA)
Number of subjects: 0
Study 34078342 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behaviour intervention (iSED)
Number of subjects: 0
Study 32719251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic preparation Yashtimadhu in addition to conventional treatment
Number of subjects: 0
Study 32719251 — intervention group
Group type: COMPARATOR
Intervention: Conventional mucositis treatment
Number of subjects: 0
Study 32719251 — intervention group
Group type: COMPARATOR
Intervention: Honey for local application and oral intake in addition to routine conventional treatment
Number of subjects: 0
Study 35110418 — intervention group
Group type: EXPERIMENTAL
Intervention: RO4929097 plus vismodegib
Number of subjects: 73
Study 35110418 — intervention group
Group type: COMPARATOR
Intervention: RO4929097 alone
Number of subjects: 73
Study 33621332 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation and Exercise Treatment (MedExT)
Number of subjects: 38
Study 33621332 — intervention group
Group type: COMPARATOR
Intervention: Audiobook Control
Number of subjects: 38
Study 32340585 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 54
Study 32340585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Exercise (AE)
Number of subjects: 54
Study 32340585 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study 32340585 — intervention group
Group type: COMPARATOR
Intervention: All groups (including Control)
Number of subjects: 54
Study 35372428 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Foam Pillow (MFP)
Number of subjects: 32
Study 35372428 — intervention group
Group type: EXPERIMENTAL
Intervention: Own Pillow (OP)
Number of subjects: 32
Study 33092813 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 93
Study 33092813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS)
Number of subjects: 93
Study 33092813 — intervention group
Group type: COMPARATOR
Intervention: Dietetic regulation and Kegal exercises
Number of subjects: 93